Associated Papers
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
Mast Cell Leukemia With Myelodysplastic Syndrome With a KIT D816V Mutation and a GATA2 Germline Mutation in a Child: Case Report and Literature Review.
Zheng F et al.
Pediatric Blood & Cancer, 2025
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
Cheng WY et al.
Blood, 2025
Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial).
Falkenhorst J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Novel KIT mutation, D816_N819delinsll, in a patient with systemic mastocytosis: a case report.
Juratli HA et al.
Virchows Archiv : an International Journal of Pathology, 2025
Whole-exome sequencing has revealed novel genetic characteristics in intracranial germ cell tumours in the Chinese.
Huang X et al.
Histopathology, 2024
Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia.
Liu Y et al.
Heliyon, 2024
KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1.
Srinivasan S et al.
Pediatric Blood & Cancer, 2024
Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation.
Sandow L et al.
Leukemia Research Reports, 2024
Standing in the canine precision medicine knowledge gap: Improving annotation of canine cancer genomic biomarkers through systematic comparative analysis of human cancer mutations in COSMIC.
Sakthikumar S et al.
Veterinary and Comparative Oncology, 2023
KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes.
Navarro-Navarro P et al.
Allergy, 2023
New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.
Valent P et al.
Annual Review of Pathology, 2023
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.
González-López O et al.
Cancers, 2022
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
Jeffers M et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022
Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers.
George S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification.
Liu T et al.
Nature Communications, 2022
Ovarian germ cell tumor/mastocytosis with KIT mutation: A unique clinicopathological entity.
Xiao P et al.
Genes, Chromosomes & Cancer, 2022
Monitoring Circulating Tumor DNA During Surgical Treatment in Patients with Gastrointestinal Stromal Tumors.
Johansson G et al.
Molecular Cancer Therapeutics, 2021
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 2021
Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma.
Ilcus C et al.
Journal of Personalized Medicine, 2021
Sequence Neighborhoods Enable Reliable Prediction of Pathogenic Mutations in Cancer Genomes.
Banerjee S et al.
Cancers, 2021
Molecular Characterization of Ovarian Yolk Sac Tumor (OYST).
Hodroj K et al.
Cancers, 2021
Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J et al.
Theranostics, 2021
An aggressive systemic mastocytosis preceded by ovarian dysgerminoma.
Tsutsumi M et al.
Bmc Cancer, 2020
Genomic landscape of platinum resistant and sensitive testicular cancers.
Loveday C et al.
Nature Communications, 2020
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy.
Mühlenberg T et al.
Molecular Cancer Therapeutics, 2019
D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
Yui S et al.
Annals of Hematology, 2017
Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy.
Ichimura K et al.
Acta Neuropathologica, 2016
Shared clonal cytogenetic abnormalities in aberrant mast cells and leukemic myeloid blasts detected by single nucleotide polymorphism microarray-based whole-genome scanning.
Frederiksen JK et al.
Genes, Chromosomes & Cancer, 2016
A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacological Research, 2015
Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma.
O'Donnell E et al.
Ebiomedicine, 2015
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
Systemic mastocytosis associated with t(8;21) acute myeloid leukemia in a child: detection of the D816A mutation of KIT.
Yabe M et al.
Pediatric Blood & Cancer, 2012
Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities.
Pommier SJ et al.
Annals of Surgical Oncology, 2012
Gastrointestinal stromal tumours: origin and molecular oncology.
Corless CL et al.
Nature Reviews. Cancer, 2011
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.
Dias-Santagata D et al.
Embo Molecular Medicine, 2010
Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.
Guo T et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome.
Gustafson SA et al.
American Journal of Clinical Pathology, 2009
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z et al.
Oncogene, 2009
Mutations of c-kit gene in bilateral testicular germ cell tumours in Japan.
Sakuma Y et al.
Cancer Letters, 2008